Common Contracts
3 similar Tax Matters Agreement contracts by CXApp Inc., Inpixon, Ligand Pharmaceuticals Inc
TAX MATTERS AGREEMENT by and among KINS TECHNOLOGY GROUP INC. INPIXON and CXAPP HOLDING CORP. Dated as of March 14, 2023Tax Matters Agreement • March 20th, 2023 • CXApp Inc. • Services-prepackaged software • Delaware
This TAX MATTERS AGREEMENT (this “Agreement”), is entered into as of March 14, 2023 by and among KINS Technology Group Inc., a Delaware corporation (“Parent”), Inpixon, a Nevada corporation (“Remainco”), and CXApp Holding Corp., a Delaware corporation (“Spinco” and, together with Parent and Remainco, the “Parties”). Capitalized terms used in this Agreement and not otherwise defined herein shall have the meanings ascribed to such terms in the Separation and Distribution Agreement, dated as of the date hereof, by and among the Parties (the “Separation Agreement”).
TAX MATTERS AGREEMENT by and among KINS TECHNOLOGY GROUP INC. INPIXON and CXAPP HOLDING CORP. Dated as of March 14, 2023Tax Matters Agreement • March 20th, 2023 • Inpixon • Services-computer programming services • Delaware
This TAX MATTERS AGREEMENT (this “Agreement”), is entered into as of March 14, 2023 by and among KINS Technology Group Inc., a Delaware corporation (“Parent”), Inpixon, a Nevada corporation (“Remainco”), and CXApp Holding Corp., a Delaware corporation (“Spinco” and, together with Parent and Remainco, the “Parties”). Capitalized terms used in this Agreement and not otherwise defined herein shall have the meanings ascribed to such terms in the Separation and Distribution Agreement, dated as of the date hereof, by and among the Parties (the “Separation Agreement”).
TAX MATTERS AGREEMENT by and among OMNIAB, INC. (F/K/A AVISTA PUBLIC ACQUISITION CORP. II) LIGAND PHARMACEUTICALS INCORPORATED and OMNIAB OPERATIONS, INC. (F/K/A OMNIAB, INC.) Dated as of November 1, 2022Tax Matters Agreement • November 4th, 2022 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This TAX MATTERS AGREEMENT (this “Agreement”), is entered into as of November 1, 2022 by and among OmniAb, Inc., a Delaware corporation (f/k/a Avista Public Acquisition Corp. II) (“Parent”), Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Remainco”), and OmniAb Operations, Inc., a Delaware corporation (f/k/a OmniAb, Inc.) (“Spinco” and, together with Parent and Remainco, the “Parties”). Capitalized terms used in this Agreement and not otherwise defined herein shall have the meanings ascribed to such terms in the Separation and Distribution Agreement, dated as of the date hereof, by and between the Parties (the “Separation Agreement”).
